Compare · CHRA vs NTRA
CHRA vs NTRA
Side-by-side comparison of Charah Solutions Inc. (CHRA) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- CHRA operates in Utilities, while NTRA operates in Health Care - the two are in different parts of the market.
- NTRA is the larger of the two at $30.57B, about 176.0x CHRA ($173.7M).
- NTRA has hit the wire 16 times in the past 4 weeks while CHRA has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 1 for CHRA).
- Company
- Charah Solutions Inc.
- Natera Inc.
- Price
- $2.17-7.66%
- $213.41-0.88%
- Market cap
- $173.7M
- $30.57B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 0
- 16
- Recent ratings
- 1
- 25
Charah Solutions Inc.
Charah Solutions, Inc. provides environmental services to the power generation industry in the United States. The company offers remediation and compliance services, including environmental management of landfills for coal-fired power generation facilities and new and existing ash ponds; active pond management services, such as closure by removal, cap-in-place, and design and construction of new ponds. Its remediation and compliance services also include landfill development, construction, and management; site evaluation and characterization; preliminary design and cost estimates with life-cycle analysis; hydrogeological assessment; groundwater and containment modeling; permit application and processing for expansions and greenfield sites; design engineering; construction of landfills and cap and cover systems; conversion of impoundments to landfill sites; quality assurance and control, and documentation; engineered fills (off-site); and other related services. In addition, the company recycles recurring and contracted volumes of coal-fired power generation waste byproducts comprising bottom ash, fly ash, and gypsum byproducts for the use in various industrial purposes. Further, it provides coal ash management services; fossil services that include silo management, on-site ash transportation, and capture and disposal of ash byproduct from coal power operations; and manages combustion byproducts comprising bottom ash, as well as disposal of flue gas desulfurization gypsum, Pozatec/fixated scrubber sludge, and fluidized bed combustion fly ash; and environmental risk transfer services that manages the sites' remediation requirements. Charah Solutions, Inc. was founded in 1987 and is headquartered in Louisville, Kentucky.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CHRA
- Charah Solutions Names Tony Tomljanovic as Chief Financial Officer and Treasurer
- SEC Form 15-12G filed by Charah Solutions Inc.
- Charah Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form EFFECT filed by Charah Solutions Inc.
- SEC Form SC 13D/A filed by Charah Solutions Inc. (Amendment)
- SEC Form 4 filed by Bcp Energy Services Fund Ugp, Llc
- SEC Form 4 filed by Blossman Jack A Jr
- SEC Form 4 filed by Skidmore Joseph
- SEC Form 4 filed by Whalen Dennis Thomas
- SEC Form 4 filed by Simon Timothy Alan
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma